



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

1st March 2023
EMA/831515/2022
Executive Director

Decision of the Executive Director

On rules concerning the handling of declared interests of national experts on secondment, trainees, interims visiting and collaborating experts of the European Medicines Agency

THE EXECUTIVE DIRECTOR

HAVING REGARD TO the Management Board decision on the rules relating to Articles 11, 11a and 13 of the Staff Regulations concerning the handling of declared interests of staff members of the European Medicines Agency and candidates before recruitment;

HAVING REGARD TO the Code of Conduct of the Agency adopted by its Management Board;

WHEREAS the Agency has implemented measures and controls in its processes and systems that prevent or mitigate the risk arising from potential conflicts of interest, including prohibiting certain conflicting practices, separating roles and responsibilities to reduce undue influence, and reinforcing collegial decision-making;

HAS DECIDED:

Article 1

The Management Board decision on the rules relating to Articles 11, 11a and 13 of the Staff Regulations concerning the handling of declared interests of staff members of the European Medicines Agency and candidates before recruitment', as adopted by the Management Board of the European Medicines Agency on 1 March 2023 shall apply by analogy to National Experts on Secondment, Trainees, Interims, Visiting and Collaborating Experts of the European Medicines Agency. The provisions of Articles 2(5), 5(7) and 6(7) on the retention period of declarations of interests of staff shall not apply to Visiting Experts and Trainees. The retention period for the declarations on interests of Visiting Experts and Trainees is of 2 years according to the Agency's applicable guidance for archiving and disposal of documents¹

¹ Internal guidance 0033-2021 for archiving and disposal of documents in HR Rules, Procedures and Partnerships, Staff Matters and Talent Acquisition services.



Article 2

This decision shall take effect on the date of its signature and repeals EMA previous decision EMA/78396/2012 (Rev. 1) of 01 March 2017.

[signature on file]

Emer Cooke
Executive Director